logo
A Non-Opioid Pain Medicine Exists. Will The FDA Act?

A Non-Opioid Pain Medicine Exists. Will The FDA Act?

Forbes09-04-2025

Military doctors and other soldiers carry a wounded soldier to a UH-60 medivac helicopter some 60kms ... More northeast of Baghdad 06 May 2003. The military made dramatic advances in battlefield pain management during the wars in Afghanistan and Iraq (Photo by ROBERTO SCHMIDT/AFP via Getty Images)
Morphine has been the mainstay for treating pain since the Civil War. Although doctors recognized long ago that prolonged use of morphine can lead to addiction, nothing changed for 150 years. That's because there were no practical alternatives. The good news is that an effective non-opioid pain medicine exists. The bad news is that the FDA has not yet approved the medication's use for this purpose.
Opioid abuse is ravaging families and communities across the United States. More than 81,000 opioid overdose deaths occurred in 2022, six times the number recorded in 1999. President Trump first declared the opioid crisis a public health emergency in 2017. His declaration was officially renewed in 2024. Although overdose deaths have declined somewhat in the past two years, they remain the leading cause of death among Americans aged 18-44. More must be done.
Ketamine, an anesthetic, was first approved by the FDA 50 years ago. Its low cost and wide safety margin quickly made it a popular choice for surgery worldwide. The WHO classified it as an essential medicine in 1985.
Recently, ketamine has also shown promise in treatment-resistant depression. Unfortunately, media coverage of that development, along with the rapid proliferation of 'ketamine clinics,' online prescribing and a celebrity death overshadowed another, equally promising use for ketamine: as an non-opioid alternative to treat acute pain.
Ketamine's pain-relieving properties at doses far below those required for anesthesia have been recognized for years. And unlike morphine, ketamine tends to preserve blood pressure and breathing, even when administered to unstable patients.
When the U.S. military entered Afghanistan in 2001 and Iraq in 2003, morphine was its primary drug for treating pain on the battlefield. It was soon supplemented by even more potent opioids, including fentanyl lozenges and hydromorphone. Near the end of the decade, growing concern about the opioids led military doctors to consider ketamine as an alternative.
When used to treat wounded soldiers, ketamine provides excellent pain relief. Some who receive it report little or no recall of their acute event. Based on this success, the military developed guidelines for ketamine's use, trained its medics and corpsmen to administer it and supplied the medication to units deploying for combat.
When word got out of the military's favorable experience, several civilian EMS services and hospital ERs started using ketamine 'off-label' to treat pain. Prescribing FDA-approved medications for non-FDA-approved purposes is more common than many people realize. Nearly 40% of U.S. prescriptions are written 'off-label,' according to the Congressional Research Service.
A man is loaded into an ambulance after he was injured by one of two bombs exploded during the 117th ... More Boston Marathon on April 15, 2013. (Photo by)
Over the next several years, numerous clinical trials in civilian ERs and EMS services confirmed that low-dose ketamine works faster than morphine and is as safe and effective. Based on this evidence, five emergency care organizations, ten specialty societies endorsed its use to treat severe pain in emergency care settings. So did the military's Committee on Tactical Combat Casualty Care.
Allowing medics and other emergency care professionals to administer small, fixed doses under medical supervision is safe. Using ketamine as a 'party drug' or to self-treat depression at home is not. On top of that, two heavily publicized deaths put ketamine in a bad light. Both involved highly unusual circumstances and much larger doses of ketamine than those used to treat pain.
In 2019, Elijah McClain, a young, unarmed Black man, was violently tackled by three police officers, twice put in chokeholds, and pinned to the ground. When paramedics arrived shortly thereafter, they administered a large dose of ketamine for presumed 'agitated delirium.' Shortly thereafter, Mr. McClain went into cardiac arrest. The contract medical examiner retained for the case concluded that McClain's death was 'most likely the result of ketamine toxicity.' Four years later, a Colorado jury found both paramedics guilty of negligent homicide.
In 2023, Hollywood actor Matthew Perry consumed a large quantity of ketamine and then climbed into his hot tub. Because no one was with him at the time, he drowned. Two months later, the L.A. County coroner ruled that Perry's death was caused by "acute effects of ketamine.' Drowning, along with coronary artery disease and concurrent use of an opioid, buprenorphine, were listed as 'contributing factors.'
In contrast to the annual toll of opioid-related deaths, deaths due to ketamine are rare. CDC recently analyzed four years of data on fatal drug overdoses reported by 44 states and the District of Columbia. A total of 228,668 deaths were identified. Ketamine was detected among other drugs in 912 (0.4%) of these fatalities, listed as 'involved' in 440 (0.2%), and was the only substance involved in 24 (0.01%) deaths—an average of six per year. To put this number in perspective, overdoses with acetamenophen account for about 500 deaths per year in the U.S.
Because the FDA has only approved ketamine as an anesthetic, manufacturers produce it in multidose vials of three different strengths. In high-stress emergencies, calculating the correct dose to withdraw from a vial takes time and increases the risk of error. This is why, for more than a decade, the U.S. military has sought FDA approval of ketamine to treat severe pain in combat and other time-urgent emergency care settings.
If (or more likely, when) the FDA finally grants approval, military and civilian teams should be able to acquire prepackaged doses of ketamine or better yet, preloaded automatic injectors that will enable them to relieve the pain experienced by seriously injured patients more quickly and safely. Additionally, pre-loaded injectors are more difficult to divert than multi-dose vials.
Food And Drug Administration headquarters in White Oak, Maryland. (Photo by Sarah Silbiger/Getty ... More Images)
Rather than accept the large body of real-world evidence of the safety and efficacy of low-dose ketamine as an analgesic, the FDA wants additional studies done to pinpoint the best dose and to prove to its satisfaction that this battle-tested drug is effective at reducing or relieving pain. This will take time and money. If the FDA does not reconsider its position, I hope that the U.S. military quickly sponsors the needed research so its medics, corpsmen and doctors, as well as civilian EMS and ER staff, can reduce their longstanding reliance on morphine, fentanyl, and other opioid analgesics to treat severe pain.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest
Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest

Wall Street Journal

time32 minutes ago

  • Wall Street Journal

Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest

Omada Health is making its public-market debut, propelled by Americans' renewed focus on how weight affects physical health. The virtual healthcare platform on Friday will start trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy and Mounjaro have sparked renewed focus on health problems that can stem from obesity, President Wei-Li Shao said.

United Health Products Provides Regulatory Application Update
United Health Products Provides Regulatory Application Update

Associated Press

time40 minutes ago

  • Associated Press

United Health Products Provides Regulatory Application Update

MT. LAUREL, NJ - June 6, 2025 ( NEWMEDIAWIRE ) - United Health Products, Inc. (OTCQB: UEEC) today provided a status update on its discussion with the Food & Drug Administration. As previously disclosed, the review by FDA's Office of Product Evaluation and Quality of its Investigational Device Exemption (IDE) application to conduct the follow-on clinical study of 27 patients undergoing organ space procedures found no deficiencies but stated that the company must address the findings set forth in the assessment of the Bioresearch Monitoring (BIMO) audit of its initial 2019 clinical study. The assessment was issued by the Division of Clinical Policy and Quality on March 24, 2025, and the company submitted its detailed response addressing all findings on April 14. As of the current date, the FDA states that its review of the company's response is ongoing. Pending the resolution of the BIMO Audit assessment, the company has completed all study tasks that can be accomplished prior to the IDE approval so that patient enrollment can begin as soon as possible thereafter. About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market. For more information on UHP visit the company's new website: or contact the company at [email protected]. The company can also be reached by phone or text message at 475.755.1005. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipates' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. View the original release on

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Associated Press

time40 minutes ago

  • Associated Press

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. 'These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options,' said Robert Berman, enVVeno Medical's Chief Executive Officer. 'Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option.' Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, 'Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve' today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the 'Company') related thereto contain, or may contain, among other things, certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as 'projects,' 'may,' 'will,' 'could,' 'would,' 'should,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'potential' or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLC [email protected] (908) 824-0775 MEDIA CONTACT: Glenn Silver, FINN Partners [email protected] (973) 818-8198 SOURCE: enVVeno Medical Corporation press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store